(Q34052852)

30 July 2017

1 reference

title

Relationship between disease activity and dose-response relationships with beta interferon therapies in the treatment of multiple sclerosis (English)

1 reference

30 July 2017

0 references

Jeffery DR

1

1 reference

30 July 2017

publication date

1 September 2000

1 reference

Journal of the Neurological Sciences

30 July 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

30 July 2017

volume

178

1 reference

30 July 2017

issue

1

1 reference

30 July 2017

page(s)

2-9

1 reference

How many people in the world have multiple sclerosis?

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

The natural history of multiple sclerosis: a regional study with some longitudinal data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Multiple sclerosis. The spectrum of severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Magnetic resonance in monitoring the treatment of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Axonal transection in the lesions of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

A pilot study of MRI activity before and during interferon beta-1a therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

The natural history of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Spinal cord atrophy and disability in MS: A longitudinal study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Improved correlation between scores on the expanded disability status scale and cerebral lesion load in relapsing-remitting multiple sclerosis. Results of the application of new imaging methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Spinal cord atrophy and disability in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

A one year study of new lesions in multiple sclerosis using monthly gadolinium enhanced MRI: Correlations with changes of T2 and magnetization transfer lesion loads

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: relation to inflammatory activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Determinants of Gd-enhanced MRI response to IFN-beta-1a treatment in relapsing-remitting multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

MRI dynamics of brain and spinal cord in progressive multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Interferon beta therapy for multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Interferons should be used to treat most patients with MS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

The treatment of chronic progressive multiple sclerosis with cladribine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Cladribine treatment of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Cladribine in treatment of chronic progressive multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Outcomes assessment in multiple sclerosis clinical trials: a critical analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900358-0

10.1016/S0022-510X(00)00358-0

7 January 2021

Identifiers

DOI

1 reference

30 July 2017

1 reference